Addition of lenalidomide to standard chemotherapy in patients with MYC overexpressing DLBCL is safe and results in comparable responses to outcomes of intensified chemotherapy regimens [158]. The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.